Souhaitez-vous accéder aux communiqués récents ?

-- Acquisition of EK-Pack latest investment to bolster commitment to customers throughout Europe. Philadelphia, United States, AND Wiggensbach, Germany (29 June 2023) – Oliver Healthcare...

- Klinische Erprobung von MyopiaX®, dem ersten Ansatz zur digitalen Behandlung von Kurzsichtigkeit bei Kindern beruhend auf dem Dopamin-Signalweg - Aufnahme von Patienten in Deutschland, Spanien,...

- Primer ensayo clínico en humanos de MyopiaX® , el primer enfoque terapéutico para la miopía juvenil dirigido digitalmente a la vía dopaminérgica.- Inscripción en curso en Alemania, España, Países...

- First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally- Enrollment ongoing in Germany, Spain, the Netherlands, and the...

IMAGIO consortium of clinical partners coordinated by Philips receives EUR 24 million grant from the Innovative Health Initiative (IHI) and additional funding from industry partners to support the...

Data presented at the 24th EFFORT Congress in Vienna (Austria) Leipzig, Germany, June 20, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using...

FDA grants orphan drug designation for MetrioPharm’s lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)DMD is a designated orphan disease in both Europe and the...

Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late...

-    Addressing high unmet medical need in locally advanced soft tissue sarcoma-    Targeted tumor treatment independent of specific molecular targets or tumor subtypes Munich, Germany – May 24,...

- First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...